Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Full-text index only
Bladder tumour-derived somatic TSC1 missense mutations cause loss of function via distinct mechanisms.
PMID 18397877 · PMC2427143 · Human molecular genetics · 2008 · 8 claims · 8 setups
All six somatic TSC1 missense mutations found in bladder tumours cause loss of TSC1 function, but via distinct molecular mechanisms.
-
Full-text index only
Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy.
PMID 18212748 · PMC2243141 · British journal of cancer · 2008 · 5 claims · 6 setups
LC-MS/MS proteomic analysis of stage I lung adenocarcinoma specimens identified myosin IIA and vimentin as candidate biomarker proteins with signal intensities that differed significantly among patient outcome groups
-
Full-text index only
Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver.
PMID 10362118 · PMC2363034 · British journal of cancer · 1999 · 7 claims · 6 setups
p73 protein is expressed (nuclear immunostaining) in a substantial subset of cholangiocellular carcinomas
-
Full-text index only
Dominant clones leverage developmental epigenomic states to drive ependymoma.
PMID 41882368 · PMC13102692 · Nature · 2026 · 8 claims · 8 setups
Chromatin accessibility patterns in neural progenitor cells are pre-established during normal development and are subsequently commissioned (not created) by ZR binding to drive oncogene expression
-
Full-text index only
Synthetic super-enhancers enable precision viral immunotherapy.
PMID 41951744 · PMC13149004 · Nature · 2026 · 8 claims · 8 setups
Synthetic super-enhancers (SSEs) assembled from validated 160 bp SOX2/SOX9-bound enhancer fragments achieve strong and highly selective transcriptional activity in glioblastoma stem cells (GSCs)